Article -> Article Details

Dry Eye Syndrome Market -Overview

The increased exposure to electronic devices has increased dry eye syndrome incidence, thus bolstering the global market. The pharmaceutical industry reports are designed by Market Research Future, highlighting market prospects for evolution. A 6.6% CAGR is projected to bolster the market in the forecast period.

The high prevalence of contact lens usage in urban areas is projected to add considerably to the market share’s dry eye syndrome. The segments of prescription type, branded drugs, and generic drugs are projected to enhance the approaching period’s eye syndrome treatment market.

Dry Eye Syndrome Market Segmental Analysis

The segmental insight into the dry eye syndrome market is based on treatment, distribution channel, type, diagnosis, region, and end-user. The type segment of the dry eye syndrome market includes aqueous dry eye syndrome, evaporative dry eye syndrome, and others. The regions analyzed in the dry eye syndrome market are the Americas, Europe, Africa, the Middle East, and Europe. The diagnosis segment in the dry eye syndrome market includes eye exam, Schirmer test, and others.   The end-user segment of the dry eye syndrome market consists of hospitals, clinics, home care, etc. The treatment-based segment of the dry eye syndrome market includes surgery, serum eye drops, lubricant eye drops, nutritional supplements, anti-inflammatory drugs segments, and others. The distribution channel-based evaluation of the dry eye syndrome market comprises of retail pharmacies, online pharmacies, hospital pharmacies, and others.

Dry Eye Syndrome Market Regional Analysis 

The regions analyzed in the dry eye syndrome market are the Americas, Europe, Africa, the Middle East, and Europe. The Americas has created a lead in the global market attributed to the existence of a complex healthcare sector and a huge patient population. Furthermore, increasing healthcare spending lifts the development of the American dry eye syndrome market. The European dry eye syndrome market is the next principal dry eye syndrome market due to growing accessibility to resources for research, a sophisticated healthcare sector, an enormous patient pool, and a growing geriatric population. The Asia Pacific is the speediest in terms of its growth due to the incidence of national markets like India, China, Australia, and others. Furthermore, the massive patient population and intensifying healthcare spending contribute to boosting the dry eye syndrome market growth. The Middle Eastern and African regions have the smallest stake but this is estimated to change because of the progress in the healthcare sector and enormous healthcare spending by the advanced economies in the region.

Dry Eye Syndrome Market Competitive Analysis

The microeconomic level improvement is estimated to have its presence felt on the global level as companies are driven to undertake new ventures for growth. The revision of supply chain comments is estimated to have a conducive effect on the long-term expansion of the players operating in the market. The positive response to the development of a COVID-19 vaccine is estimated to provide further reassurance to the companies regarding their future progress. The market is estimated to draw heavily from the market cues on a global scale while monitoring their consumer base in the forecast period. The influence of government backup is foreseen to have a fortifying effect on the market’s development in diverse markets worldwide. The large-scale integration of technology in various areas of the market is predicted to lead the global market to new efficiency levels in the forecast period. The market players are also assessed to take a venture into broadening their commercial interests through the upcoming period with several smaller businesses unable to maintain financial viability.

The vital players in dry eye syndrome are Novartis AG (Switzerland), Acadia Pharmaceutical (U.S.), Allostera Pharma (Canada), Otsuka Pharmaceutical Co. Ltd. (Japan), I-Med Pharma Inc. (Canada), Allergan (Republic of Ireland), Valent Pharmaceuticals (Canada), Johnson & Johnson Vision (U.S.), Santen Pharmaceuticals Co. Ltd., (Japan), AFT pharmaceuticals (New Zealand), Novaliq GmBh (Germany), Auven therapeutics (U.S.), and others.